|

Utilizing the Michigan Neuropathy Screening Instrument for Early Detection of Diabetic Neuropathy

RECRUITINGSponsored by Sohag University
Actively Recruiting
SponsorSohag University
Started2023-06-01
Est. completion2025-06-01
Eligibility
Age33 Years – 65 Years
View on ClinicalTrials.gov →

NCT06514846

Summary

The study aims to Compare the diagnostic accuracy of the Michigan Neuropathy Screening Instrument (MNSI) (using MNS questionnaire, ,Inspection, vibratory sensation, Ankle reflexes Exam, 10 g monofilament needle examination), routine NCS, and the U/S of the median, posterior tibial, and sural nerves in identifying diabetic peripheral neuropathy in patients recently diagnosed with type 2 diabetes.

Eligibility

Age: 33 Years – 65 Years
Inclusion Criteria:

* ü Age: 30-55 y

ü Type of diabetes: Type 2

ü Duration of diabetes: Within 1Year of diagnosis of Type 2 diabetes mellitus according to World Health Organization 1999 criteria

Exclusion Criteria:

* Patients who had known conditions that could present with neuropathy such as hereditary sensory neuropathy, vitamin B12 or folate deficiency, paraneoplastic conditions, autoimmune diseases, uremia, hypothyroidism, and ethanol abuse.

Conditions2

DiabetesDiabetic Polyneuropathy

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.